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The cancer stem cell (CSC) model suggests that there are subsets of cells within a
tumor with increased proliferation and self-renewal capacity, which play a key role in
therapeutic resistance. The importance of cyclooxygenase-2 (COX-2) in carcinogenesis
has been previously established and the use of COX-2 inhibitors as celecoxib has been
shown to exert antitumor effects. The present study investigated whether treatment
of esophageal adenocarcinoma (EAC) cells with 5-fluorouracil (5-FU) or the growth of
tumor spheres increased the proportion of CSCs and also if treatment with celecoxib
was able to reduce the putative CSC markers in this tumor. OE19 and OE33 EAC cells
surviving 5-FU exposure exhibited an increase in CSC markers CD24 and ABCG2 and
also an increased resistance to apoptosis. EAC cell lines had the capacity to formmultiple
spheres displaying typical CSC functionalities such as self-renewal and increased CD24
levels. In addition, after the induction of differentiation, cancer cells reached levels of
CD24 similar to those observed in the parental cells. Treatment with celecoxib alone or
in combination with 5-FU also resulted in a reduction of CD24 expression. Moreover,
celecoxib inhibited the growth of tumor spheres. These findings showing a reduction
in CSC markers induced by celecoxib suggest that the COX-2 inhibitor might be a
candidate for combined chemotherapy in the treatment of EAC. However, additional
clinical and experimental studies are needed.
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INTRODUCTION
The incidence of EAC has increased dramatically in the last decade in western countries. This tumor
has a high index of radio- and chemo-resistance, and is frequently diagnosed at an advanced state;
therefore, EAC has poor prognosis with a 5-year survival rate ranging from 15 to 39% despite the
use of combined therapies (van Lanschot et al., 2002; DeMeester, 2006).
The limited effectiveness of standard anticancer therapies has been attributed to the presence
of cancer stem cells. The CSC model proposes that tumors are organized hierarchically, with a
subpopulation of stem-like cells which is responsible for sustaining tumor growth. These CSCs
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have the capacity to self-renew and differentiate to generate
the cellular heterogeneity observed in tumors, and may play a
pivotal role in local invasion, metastasis, resistance to therapy,
and subsequent tumor recurrence. Cancer stem cells share
many of the properties of normal stem cells, including relative
quiescence, an active DNA-repair capacity, and resistance to
apoptosis (Reya et al., 2001; Dean et al., 2005; Dallas et al.,
2009; Yoon et al., 2014). Previous reports have demonstrated
that chemoresistant cells are enriched for CSC markers and that
chemotherapy can lead to the propagation of CSCs and prevent
their differentiation (Levina et al., 2008; Dallas et al., 2009;
Abubaker et al., 2013; Canter et al., 2014). Thus, the identification
of CSCs is important because it might provide new targets for
cancer therapy and may be used to develop a new class of
biomarkers.
Experimental and clinical studies have demonstrated the
existence of CSCs in a wide range of hematopoietic and solid
tumors including colon, breast, prostate, pancreas, brain, and
liver (Al-Hajj et al., 2003; Singh et al., 2003; Kristiansen et al.,
2004a; Haraguchi et al., 2005; Li et al., 2007; Yu et al., 2009; Zhang
et al., 2010; Cao et al., 2011; Zhao et al., 2012; Liu et al., 2013).
These cells are characterized by a distinctive profile of surface
markers, their ability to form spheres of self-replicating cells in
vitro, and the capacity to form tumors in immunodeficient mice
(Reya et al., 2001; Rosen and Jordan, 2009).
To date, definitive cell surface immunophenotypes have not
been defined for most of CSCs and knowledge about CSCs in
EAC is very limited. Previous reports identified a side population
in EAC cell lines, and CD34 was reported as a potential stem cell
marker in the mouse esophagus (Haraguchi et al., 2005; Kalabis
et al., 2008; von Rahden et al., 2011; Zhang et al., 2012; Zhao et al.,
2012). Studies in human EAC tissues identified a tumor-initiating
stem-like subpopulation of cells which did not express any of the
common cell surface markers identified as CSC markers in other
types of cancer (Grotenhuis et al., 2010).
COX-2 are membrane proteins that catalyze prostaglandins
production. COX-2 overexpression is related to the development
of GI cancers, and epidemiological studies have shown
that nonsteroidal anti-inflammatory drugs (NSAIDs) exert
chemopreventive effects on EAC (Farrow et al., 1998; Anderson
et al., 2006; Abnet et al., 2009). Celecoxib, a COX-2 specific
inhibitor, has also been tested as a chemotherapeutic agent,
decreasing the neoplastic aggressiveness of esophageal
adenocarcinoma when used as neoadjuvant therapy (Tuynman
et al., 2005). Nowadays there are clinical reports of the
effectiveness of combining selective COX-2 inhibitors with
chemotherapy to treat digestive tract tumors, but the exact
mechanism underlying the anti-tumor effects remain unclear
(Dawson et al., 2007; Altorki et al., 2011).
Given the relationship between chemoresistance and the CSC
phenotype, our first approach was to analyze whether esophageal
cancer cells that survived drug treatment were enriched in
CSC markers (previously established as CSC markers in other
human cancers), and to investigate the CSC phenotype in
esophageal spheres from cancer cell lines. Finally, we investigated
if celecoxib could be related on the suppression of those markers
in chemotherapy-induced CSCs.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
The EAC cell lines (OE19 and OE33) were derived from human
EAC and were purchased from the European Collection of
Cell Cultures (ECACC; Sigma, St. Louis, MO). The OE33 cell
line was established from an adenocarcinoma of the lower
esophagus arising in Barrett’s esophagus and exhibited poor
differentiation. The OE19 cell line was established from an
adenocarcinoma of gastric cardia/esophageal gastric junction and
exhibited moderate differentiation.
Cells were cultured in RPMI 1640medium supplemented with
2 mM glutamine containing 10% fetal bovine serum (FBS) and
antibiotics (100U/mL penicillin G, 100µg/mL streptomycin, and
0.25 µg/mL amphotericin) in a humidified atmosphere of 5%
CO2/95% air at 37◦C.
MTT Assay
The effect of 5-FU (Sigma) treatment on cell viability was
evaluated by MTT. Briefly, EAC cells were seeded in 96-well-
plates at a density of 2,500 cells/well in 200 µL of medium. After
seeding, cells were incubated overnight. The following day, cells
were treated with different concentrations of 5-FU (1, 10, 50, or
100µg/mL), and then incubated for 72 h. Next, cells were washed
and treated with MTT for at least 2 h. Colorimetric analysis
was performed at a wavelength of 570 nm using a standard
microplate reader. To determine cell viability, percent viability
was calculated as [(absorbance of drug-treated) sample/(control
absorbance)] × 100. 5-FU was dissolved in DMSO as a stock
solution. All the assays were performed in triplicates, in three
independent experiments.
RNA Extraction and Gene Expression
Analysis
Cells were grown in culture in 175-cm2 flasks until they reached
70–80% confluence. Then, cells were treated with 5-FU at IC50
concentration (10 µg/mL). After 72 h of treatment, cells were
rinsed with PBS, and the surviving cells were subjected to RNA
extraction using an RNeasy Fibrous Tissue Kit (Qiagen, Crawley,
Surrey, UK) according to the manufacturer’s instructions. The
total RNA isolated was purified using RNeasyMini Elute Cleanup
(Qiagen) and quantified by spectrophotometry.
Relative gene expression was determined using the GeXP
genetic analysis system (Beckman Coulter, Barcelona, Spain),
which allows multiplex detection and quantitation of gene sets
in a single analysis (Rai et al., 2009). RT reactions (10 µL)
contained 50 ng RNA, 200 nM reverse primers, 2.5µL kanamycin
resistant (Kanr) RNA, 2 µL 5X RT Master Mix buffer, and
0.5 µL reverse transcriptase. The conditions of RT reactions
were: 1min at 48◦C, 5min at 37◦C, 60min at 42◦C, and
5min at 95◦C. Reverse transcriptase, RT master mix buffer,
and Kanr RNA were supplied in Genome Lab GeXP Start Kit.
Intron spanning primers were designed using the GenomeLab
eXpress Designer software and expression analysis was done with
the GenomeLab eXpress Profiling software (Beckman Coulter).
Multiplex amplified fragments were separated on a GenomeLab
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XP capillary sequencer and peak areas were normalized using a
reference gene to calculate relative gene expression.
The PCR reaction was performed using 4.65 µL of the 10 µL
RT reaction and a final concentration of 200 nM forward primer.
25 mMMgCl2, 5X PCR buffer, and ThermoTaq polymerase were
also added at the concentrations indicated in the Genome Lab
GeXP Start Kit. The PCR reaction conditions were: 10min at
95◦C; followed by 35 cycles of 30 s at 94◦C, 30 s at 55◦C, and 1min
at 68◦C. PCR products were analyzed on the GeXP after dilution
(800x) with sample loading solution. Kanamycin was used as the
RNA internal positive control.
We determined the expression of CD24, CD34, CD44, CD133,
ESA, ABCG2, BAX, BCL2L1, and LGR5 genes. For relative gene
expression calculation, raw data for each gene were normalized
to the housekeeping gene TBP and were subsequently calculated
relative to an internal standard (Kanr gene). The primers are
summarized in Table 1. All the experiments were performed in
triplicate.
Immunofluorescence Staining of Cells
Cells were grown on sterile coverslips placed in 24-well-plates.
After 72 h, cells were washed and fixed in methanol for 15min
at −20◦C. Cells were then incubated with the primary CD24
antibody (diluted 1/100 in PBS/1% BSA; clone 32D12, Dianova,
Hamburg, Germany) or ESA antibody (diluted 1/200; Abcam,
MA USA) for 90min at room temperature in a high-humidity
chamber. After washing twice with PBS, the Alexa Fluor 488
goat anti-mouse (1/250 dilution) and Alexa Fluor 488 goat
anti-rabbit (1/250 dilution) were added, respectively, and cells
were incubated at room temperature for 1 h in a high-humidity
chamber.
After several washes, coverglasses were mounted on
glass slides using Mowiol. Preparations were observed in a
fluorescence microscope (Olympus IX81, Tokyo, Japan).
Flow Cytometry Assay
Control and 5-FU-treated (10 µg/mL) EAC cells were subjected
to flow cytometry analyses to determine CD24 and ESA levels.
Briefly, the cells were harvested, centrifuged, and suspended in
50 µl PBS. Cells were then incubated with 5 µl mouse anti-
human CD24-PE antibody (clone ALB9; Immunotech, Marseille,
France) or ESA-FITC antibody (clone ESA214; GeneTex, Irvine,
CA) for 15min at 4◦C. Mouse anti-human IgG1-PE and mouse
anti-human IgG1-FITC were used as isotype controls for CD24
and ESA, respectively. Samples were analyzed with a FACSAria
cell sorter (BD Biosciences, San Jose, CA, USA).
Similarly, tumor spheres and cells treated with celecoxib
were subjected to flow cytometric analysis to examine CD24
expression. All the experiments were performed at least three
times.
Sphere Formation Assay
Tumor sphere cultures were established from trypsinized cells
from adherent cultures of the parental OE33 and OE19 cell
lines. For the formation of esophageal spheres, cells were plated
in 25 cm2 ultra-low attachment flasks (Corning, Tewksbury,
MA, USA) and cultured in serum-free Dulbecco’s modified
eagle medium (DMEM-F12, Sigma) containing: 5 µg/mL
insuline (Sigma), 0.4% bovine serum albumin (Sigma), 10
ng/mL human basic fibroblast growth factor (bFGF; Sigma),
20 ng/mL epidermal growth factor (EGF; Sigma), 2% B27
Supplement (Invitrogen Corporation, Grand Island, NY) and
antibiotic/antimycotic (Sigma). Cells were supplemented with
freshmedium and growth factors twice weekly. At day 14, spheres
>40 µm in diameter were collected using a cell strainer (BD),
dissociated to single cells, and reseeded to evaluate self-renewal
through the formation of a second generation of tumor spheres.
In order to determinate putative CSC markers, an aliquot was
analyzed by flow cytometry.
For differentiation assays, disaggregated spheres were seeded
in RPMI 1640 medium with 10% FCS in adherent conditions.
In another set of experiments, OE33 cells were plated for the
formation of esophageal spheres and then treated with celecoxib
(10, 20, or 40 µM) for 7 days. Thus, we determined the size of
spheres using Image J software at days 2 and 7 by measuring
sphere diameter.
Statistical Analysis
Results are expressed asmean± SEM. Student t-tests and analysis
of variance followed by a Dunnet’s test were used to calculate the
statistical differences, and p < 0.05 was considered statistically
significant.
TABLE 1 | PCR primers for multiplex-PCR.
Gene/symbol Accession N◦ Primer Forward (5′–3′) Primer Reverse (5′–3′) Size (bp)
CD24 NM_013230 GAGACCACGAAGAGACTGGC ACCCACGCAGATTTATTCCA 156
CD34 NM_001773 CTGGAGTTGAAACGTTGGCT GGCCACAACAAACATCACAG 149
CD44 NM_001001392 CAGGTCTCAAATCCGATGCT TACAGCATCTCTCGGACGG 107
CD133 NM_006017 GGCTAGTTTTCACGCTGGTC ACCGACTGAGACCCAACATC 165
ESA NM_004475 GCTGCACAACCTCAATCTCA TCAGCCTTCAGTGAGGAGGT 121
ABCG2 NM_004827 AAGCCATTGGTGTTTCCTTG TGAGCCTTTGGTTAAGACCG 114
BAX NM_004324 GCCACTCGGAAAAAGACCTC CAGCTCTGAGCAGATCATGAAG 246
BCL2L1 (BCL2-like1) NM_138578.1 GTATCACAGGTCGGGAGAGG CAATTCCTGTGTCGCCTTCT 142
Lgr5 NM_003667 GCAGACGGTTTGAGGAAGAG CCCCACTGCAATTAGGACAC 298
TBP NM_003194 GGAGGCAAGGGTACATGAGA CCCCACTGCAATTAGGACAC 268
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RESULTS
Enrichment in Cancer Stem Cell Markers
by Exposing Cells to 5-FU
MTT assay was used to establish IC50-value for 5-FU in our cell
lines. IC50 doses were obtained from the dose-response curves
(GraphPad Prism 4.0, La Jolla, CA, USA) and were established
at 10 µg/mL for OE33 cell line and 10.96 µg/mL for OE19
cell line (Figure 1). The fraction that survived 5-FU exposure
was characterized for cancer stem phenotype and examined for
enrichment in cancer stem markers.
To characterize whether cells that survived 5-FU exposure
were related to the cancer stem phenotype, we compared
gene expression of genes involved in cell survival (BAX and
BCLL2) and drug resistance (ABCG2) among cells surviving 5-
FU exposure and control cells. Using the GeXP genetic analysis
system, we determined mRNA expression of the BAX pro-
apoptotic gene, the BCLL2 antiapoptotic gene, and the ABCG2
gene in the 5-FU-resistant fraction and in untreated cells. BCLL2
expression was significantly increased in 5-FU treated cells
(102% in OE19 cells, p = 0.001 and 51% in OE33 cells, p =
0.002) vs. untreated cells. In contrast, BAX gene expression was
significantly reduced in treated cells (28% inOE19 cells, p= 0.002
and 19% in OE33 cells, p= 0.02; Figures 2A,B).
Drug resistance of CSCs is mediated in part by the
ATP-binding cassette (ABC) drug transporters. Therefore, we
examined ABCG2 expression in these cells. Although levels of
ABCG2mRNA were increased in 5-FU-treated OE19 cells (123%
vs. control cells, p = 0.001), no difference in expression was
observed in OE33 cells (Figure 2C).
Next, we determined mRNA expression levels of a variety of
surface markers related to CSCs (CD24, CD34, CD44, CD133,
ESA, and LGR5) in the 5-FU-resistant fraction and untreated
cells. Expression of all analyzed markers was observed in both
cancer cell lines with the exception of LGR5, which was not
detected in the OE33 cell line. CD24, ESA, and CD44 were the
main CSC markers expressed. Cells surviving treatment with 5-
FU exhibited a significant increase of CD24 mRNA expression
(87% in OE19 cells, p = 0.04 and 66% in OE33 cells, p = 0.001)
and a moderate increase of ESAmRNA expression (40% in OE19
cells, p = 0.004 and 27% in OE33 cells, p = 0.005) compared
with untreated cells. No statistically significant differences were
observed when themRNA expression ofCD34,CD133, and LGR5
was analyzed. The level of CD44 mRNA was slightly increased
(18%, p= 0.027) in 5-FU treated OE33 cells (Figures 2D,E).
CD24 and ESA Protein Expression in EAC
Cell Lines
Given that identification of CSC is performed using cell surface
markers, and based on the above results, we determined by
immunofluorescence the specific cellular localization and by flow
cytometry the levels of surface protein CD24 expression and ESA
in 5-FU treated cells and in untreated cells.
CD24 staining intensity in esophageal cancer cells was very
heterogeneous; that is, not all of the tumor cells displayed similar
levels of protein expression (Figures 3A,B). The distribution of
CD24 protein was predominantly membranous in OE19 cells
(Figure 3A), while membranous and cytoplasmic staining were
observed in the OE33 cancer cell line (Figure 3B).
Flow cytometry revealed that the intensity of CD24
expression, measured as mean fluorescence units (MFI)
was significantly higher in 5-FU-treated cells than in control cells
in both cell lines (OE19 cells p = 0.046; OE33 cells p = 0.035;
Figures 4A–E).
ESA immunostaining revealed membranous and cytoplasmic
staining in both cancer cell lines (Figures 3C,D), with apparently
homogenous staining. No differences were observed in the ESA
MFI between control and treated cells (Figure 4F).
Sphere Formation
Sphere culture has been used as a method for enriching stem cells
and evaluating the stem cell self-renewal process. Therefore, we
investigated whether EAC cells were able to form spheres in vitro
when plated in a serum-free media supplemented with growth
factors and in anchorage-independent conditions, which allow
stem cells to maintain an undifferentiated status (Singh et al.,
2003; Cao et al., 2011; Chen et al., 2012). Both esophageal cancer
cell lines had the capacity to form multiple spheres, although
OE33 cells showed a greater ability to generate spheres than
OE19 cells (Figures 5A,B). Spheres also increased in size over
FIGURE 1 | Analysis of cells chemosensitivity to 5-FU. Cell viability was measured using an MTT assay kit. The results are expressed as the mean ± SEM of cell
viability percentage in 5-FU treated cells with respect to control cells of at least three independent experiments.
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FIGURE 2 | Analysis of mRNA levels of different markers related to stem phenotype. OE33 and OE19 EAC cell lines were exposed to 5-FU for 72 h. Relative gene
expression analysis was developed in surviving cells vs. untreated cells. mRNA levels of the antiapoptotic gene BCLL2 and the proapoptotic gene BAX in OE19 (A)
and OE33 (B) cells. mRNA levels of the drug transporter ABCG2 (C). mRNA levels of CSC markers CD24, CD34, CD44, CD133, ESA, LGR5 in OE19 (D) and OE33
(E) cells. Each bar represents the relative gene expression obtained after applying the following ratio: Normalized gene expression value/Kan-r gene value. Significant
differences from the respective control values: *p < 0.05; **p < 0.01.
FIGURE 3 | Cellular distribution of CD24 and ESA markers. Immunofluorescent staining of CD24 in OE19 (A) and OE33 (B) cells and ESA in OE19 (C) and OE33 (D)
cell lines.
time (Figure 5C). After 14 days under these culture conditions,
spheres derived from OE33 cells ranged from 80 to 100 µm in
diameter and spheres derived from OE19 cells ranged from 50 to
60 µm in diameter.
Characterization of Sphere Culture
Esophageal cancer spheres displayed typical stem cell
functionalities such as self-renewal, assessed as the spheres’
capacity to produce second-generation spheres. Spheres derived
from the OE33 cancer cell line had morphological characteristics
similar to the first generation after they were passaged for at least
three generations (Figure 5D).
Finally, we evaluated whether there were differences in the
levels of CD24 expression between cells from spheres and cells
differentiated from spheres. A statistically significant higher MFI
of CD24 expression was observed in cells from spheres (75%, p
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FIGURE 4 | Analysis of CD24 and ESA expression after 5-FU treatment. Representative image of flow cytometry dot plot of CD24 expression in OE33 (A) and OE19
(C) tumor cells. Representative flow cytometry histograms displaying CD24 expression in OE33 (B) and OE19 (D) cells treated with 5-FU (10 µg/mL) for 72 h (black
line) or in cells treated with the vehicle alone (green line). Mean fluorescence intensity of CD24 (E) and ESA (F) in 5-FU treated or in control cells. All data are expressed
as the mean ± SEM of mean fluorescence units in treated cells relative to untreated cells of at least three independent experiments. Significant differences with
respect to control cells: *p < 0.05.
= 0.025) than in the parental adherent (ADH) cells. When the
cells from spheres were plated into adherent plastic plates with
a culture medium supplemented with FBS and cultivated for 4
weeks, a lower MFI of CD24 expression was observed, which
reached levels similar to the levels observed in the parental cells
(Figure 6).
Role of Celecoxib in CD24 Expression and
Tumor Sphere Formation
To assess the effects of celecoxib on CD24 expression, OE33 cells
were incubated for 72 h with celecoxib (10, 20, or 40 µM) alone
or in combination with 5-FU (10 µg/mL), and CD24 MFI was
analized by flow cytometry. When cells were treated with 5-FU
alone, CD24 expression was increased with respect to untreated
cells. However, when cells were co-treated with 5-FU and 40
µM celecoxib, we found that celecoxib significantly attenuated 5-
FU-induced CD24 expression (p = 0.017). Likewise, cells treated
with 40 µM celecoxib alone also showed a reduction of CD24
compared with the corresponding untreated controls (p= 0.034).
No effect was observed at the other doses of celecoxib tested
(Figures 7A,B).
To evaluate the effects of celecoxib on tumor sphere
formation, OE33 cells were grown as tumor spheres and
incubated with celecoxib (10, 20, or 40 µM) for 7 days. We
monitored the size of spheres in the different experimental
conditions (control and treatment) by measuring the diameter of
the spheres with a well-defined spherical shape (Figure 8A). After
7 days of treatment, celecoxib (40 µM) significantly inhibited
the growth of the spheres compared to untreated (control) cells
(p= 0.01).
In some cases, we also observed that the treatment of
spheres with celecoxib for 7 days resulted in the disintegration
of these spheres compared with the corresponding controls
(Figure 8B).
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FIGURE 5 | Sphere formation assay. Representative phase contrast photomicrographs of tumor spheres generated by suspension culture of OE19 (A) and OE33 (B)
EAC cells after 14 days of culture. Representative images of first-generation spheres’ growth, established from adherent cultures (C). Representative images of the
first-generation of spheres (corresponding to spheres 10 days after seeding, as previously shown in Figure 4C) and two successive generations of spheres (D).
FIGURE 6 | Flow cytometric analysis of CD24 expression in adherent OE33
cells, OE33 spheres and differentiated spheres. All the results were expressed
as mean ± SEM of mean fluorescence units of three independent
experiments. *p < 0.05 with respect to adherent cells.
DISCUSSION
CSCs research might offer a new class of oncologic biomarkers
thatmay improve the diagnosis, prognosis, treatment, and/or risk
of progression in premalignant lesions.
The enrichment of CSCs after chemotherapy treatment has
been observed in in vitro models, as well as in clinical practice.
In vitro models have demonstrated that CSCs can be selected
from the parental population of tumor cells by treating cells with
chemotherapy drugs (Levina et al., 2008; Yu et al., 2009; Zhang
et al., 2010; Abubaker et al., 2013; Canter et al., 2014). In the
clinical practice, it has been reported that tumors from patients
treated with chemotherapy exhibited a higher proportion of
CSCs than tumors from untreated patients (Yu et al., 2007; Li
et al., 2008). Therefore, our first objective was to investigate the
presence of cell-surface markers related to the stem phenotype
implicated in chemoresistance on esophageal cancer cells. 5-
FU-treated OE19 cells showed elevated expression of ABCG2,
and both tested cell lines exhibited increased resistance to
apoptosis, properties consistent with stem cell phenotype. In
our experiments we observed that treatment with 5-FU induced
an increase in mRNA levels of CSC markers CD24 and ESA,
but only increased levels of CD24 protein expression were
observed, which could be probably due to post-transcriptional
mechanisms.
CD24 acts as a ligand for P-selectin and appears to contribute
to the acceleration of tumor growth and metastases (Kristiansen
et al., 2004b; Baumann et al., 2005; Burgos-Ojeda et al., 2015).
In breast cancer, CD24-expressing cancer cells can disseminate
more readily through their capacity to form thrombi with
platelets or bind to endothelial cells in the bloodstream (Aigner
et al., 1998). The loss of CD24 function has also been related with
induction of apoptosis and decreased rates of cell proliferation in
several tumor cell lines (Smith et al., 2006).
Frontiers in Pharmacology | www.frontiersin.org 7 May 2017 | Volume 8 | Article 321
Jiménez et al. 5-FU-Induced CD24 Expression Esophageal Adenocarcinoma
FIGURE 7 | Effects of celecoxib and/or 5-FU on CD24 expression. The effects of the treatment were expressed as mean fluorescence units of OE33 cells treated with
different concentrations of celecoxib (0–40 µM) alone (A) or in combination with 5-FU (10 µg/mL) (B) with respect to control (untreated) cells. All the results were
expressed as mean ± SEM of mean fluorescence units in treated cells relative to untreated cells of three independent experiments. *p < 0.05 vs. control; †p < 0.05
vs. 5-FU alone.
FIGURE 8 | Effects of celecoxib on of esophageal tumor spheres’ growth. Diameter of OE33 spheres after exposure to celecoxib (0–40 µM) for 2 or 7 days (A). All the
results were expressed as mean ± SEM of the diameter of spheres of three independent experiments. †p < 0.05, diameter of untreated spheres at day 2 vs. diameter
of untreated spheres at day 7; *p < 0.05, diameter of spheres treated with celecoxib (40 µM) vs. untreated control at day 7. A representative photograph showing the
disintegration of OE33 spheres after incubation with 40 µM celecoxib for 7 days (B, right) (200 × magnification).
In recent years, CD24 overexpression has been correlated with
shorter patient survival in breast cancer, ovarian cancer, non-
small cell lung carcinomas, prostate tumors, colorectal cancer,
and in esophageal squamous cell carcinoma (Kristiansen et al.,
2002, 2003, 2004a; Choi et al., 2005; Sano et al., 2009; Majores
et al., 2015; Wang et al., 2016). CD24 expression has also been
associated with bladder tumor recurrence (Liu et al., 2013). CD24
upregulation has been shown during the progression of colorectal
cancer and has been considered a potential target for early
intervention in the prevention and treatment of colorectal cancer
(Sagiv et al., 2006, 2008; Kraus et al., 2015). CD24 is considered
one of the surface markers associated with CSCs, mainly in the
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pancreas (Li et al., 2007). Heterogeneous staining/expression of
cell-surface antigens has previously been documented and has
been recognized in normal cells, in tumor cells, and also in long-
established tumor cell lines (Edwards, 1985; Jungbluth et al.,
2001; Al-Hajj et al., 2003). In our study, we observed higherCD24
expression in cells that survived chemotherapy, as well as in OE33
sphere-forming cells compared with adherent cells. Moreover,
we found that esophageal tumor cells exhibited heterogeneous
CD24 protein expression, suggesting the presence of different
populations or cells with different differentiation states within
the EAC cell culture. Although CD24 is a membrane receptor,
we observed membranous and cytoplasmic immunostaining
in the present study. OE19 cells, a cell line obtained from a
well-differentiated tumor, showed membranous staining; while
OE33 cells, derived from a poorly differentiated adenocarcinoma,
displayed strong cytoplasmic staining, and focal membranous
expression. These results are in accordance with previous data
obtained in biopsy specimens from colorectal, breast, prostate,
ovarian, and gastric cancer, in which a higher cytosolic expression
of the receptor has been associated with a more invasive
phenotype and reduced patient survival (Kristiansen et al., 2002,
2003, 2004a; Choi et al., 2005; Weichert et al., 2005; Chou et al.,
2007; Sano et al., 2009; Majores et al., 2015). The biological
significance of the shift from the normal membranous expression
to the cytoplasmic location of CD24 is still unclear, and might
be due to accumulation in membrane vesicles released into the
cytosol.
The model of tumor sphere formation has been shown to
closely mimic phenotype characteristics of in vivo solid tumors,
and to allow in vitro propagation of CSCs (Weiswald et al.,
2010). In colon cancer, primary tumors exhibited a correlation
between tumor aggressiveness and the ability of cancer cells
to form numerous colonospheres (Weiswald et al., 2009). In
esophageal cancer, our results showed that both EAC cell lines
formed spheres, although OE33 cells displayed a greater capacity
to form spheres.
Most oncological studies with NSAIDs have principally
focused on their potential chemopreventive effect; however,
celecoxib has also demonstrated antineoplastic activity against
different types of cancer in vitro and also in animal models
(Masferrer et al., 2000; Dannenberg and Subbaramaiah, 2003;
Koehne and Dubois, 2004; Riva et al., 2016). It has also
been suggested that celecoxib might have clinical potential as
an adjuvant therapy in patients with EAC (Tuynman et al.,
2005); however, the molecular mechanisms and cellular targets
through which celecoxib exert its anti-tumor effects are not
well-known. On one hand, there is clear evidence that COX-
2 inhibition downregulates important proteins involved in
cancer progression and dissemination, and many of the COX-
2- regulated genes may determine tumor chemosensitivity
(Dannenberg and Subbaramaiah, 2003; Tuynman et al., 2005;
Tsujii, 2013). Moreover, cultured COX-2-expressing cells from
colorectal cancer tissues exhibited several characteristics related
to stem cells, such as spheroid-forming ability, chemoresistance,
and cell cycle-arrest (Tsujii, 2013). On the other hand,
several reports indicate that anti-tumor activity of celecoxib is
independent of COX-2 inhibition (Schönthal, 2006; Ryan et al.,
2008). Thus, in colon carcinoma cell lines, both celecoxib (aCOX-
2 selective inhibitor) and SC-560 (a COX-1 selective inhibitor)
had effects on cell survival, apoptosis, and cell cycle arrest
independently of the cells’ COX-2 expression (Grösch et al.,
2001).
Our study indicates that celecoxib decreased CD24 expression
both alone and in combination with 5-FU; that is, the
increased CD24 expression observed after 5-FU administration
was attenuated when 5-FU was combined with celecoxib. Since
treatment with 40 µM celecoxib had previously shown to
decrease cell viability of OE33 cells (Tuynman et al., 2005), we
cannot discard that the reduced CD24 levels observed are due
to the cytotoxic effects of the treatment. Previous reports also
showed that increasedCD24 expression reverted to a normal level
after short (72 h) and long (6 months) exposure to celecoxib in
colon cancer (Sagiv et al., 2006). It should be noticed that, as
in the present study, those effects were also observed at higher
concentrations than those achieved in human serum following
standard anti-inflammatory dosing (Niederberger et al., 2001).
In OE33 sphere cultures, celecoxib was unable to prevent the
initiation of tumor spheres at all of the tested doses; however,
celecoxib disaggregated esophageal cancer cell spheres after
7 days of treatment, suggesting a potential role of celecoxib
in the cancer stem model. Nevertheless, a possible limitation
of our study lies in the number of cell lines evaluated, due
that the population of cancer cells within a tumor is quite
diverse and cell lines evaluated in this study could not be
sufficiently representative of the heterogeneity of the primary
tumor.
Taken together, these findings provide evidences that
esophageal cancer cell lines are heterogeneous with regard
to CD24 expression. Our observations demonstrate that
administration of the chemotherapeutic 5-FU leads to
an increase in CD24 marker expression in esophageal
adenocarcinoma cell lines, which may be related to the
stem cell phenotype, as suggested by its increased expression
in esophageal cancer spheres. Our results also suggest that
CD24 might have prognostic and therapeutic implications
for the treatment of esophageal cancer, and that celecoxib
could be evaluated as a possible candidate for combined
chemotherapy with 5-FU in the treatment of esophageal
cancer.
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